New application of 1-isobutyl-2-methylimidazole in the pharmaceutical field and its clinical research progress
The chemical structure and characteristics of 1-isobutyl-2-methylimidazole
1-isobutyl-2-methylimidazole (1-Isobutyl-2-methylimidazole, referred to as IBMI) is a compound with a unique chemical structure. Its molecular formula is C8H13N2 and its molecular weight is 135.20 g/mol. The compound consists of an imidazole ring and two substituents: one is the methyl group (-CH3) at the 2nd position and the other is the isobutyl group (-CH(CH3)2) at the 1st position. This particular structure imparts IBM a unique range of physical and chemical properties.
First, from the perspective of physical properties, IBM is a colorless or light yellow liquid at room temperature, with a lower melting point and boiling point, with a melting point of about -45°C and a boiling point of about 160°C. Its density is relatively small, about 0.92 g/cm³, and has good solubility, and can be dissolved in a variety of organic solvents, such as, and dichloromethane. In addition, IBM also has a certain volatile and hygroscopic properties, which makes it require special attention to sealing and storage during preparation and storage to avoid affecting its purity and stability due to hygroscopic absorption.
From the chemical point of view, the imidazole ring in IBM is a five-membered heterocycle containing two nitrogen atoms, one of which has a positive charge, making it highly alkaline and nucleophilic. This structure allows IBM to react with a variety of acidic substances to form stable salt compounds. For example, it can bind to halide ions (such as chloride ions, bromide ions) to form corresponding halides; it can also bind to metal ions (such as zinc ions, copper ions) to form metal complexes. These properties make IBM I have a wide range of application prospects in drug design and synthesis.
In addition, the isobutyl and methyl substituents of IBM also bring additional chemical activity to it. The presence of isobutyl increases the steric hindrance of the molecule, allowing IBM to exhibit higher selectivity and specificity when reacting with other molecules. The methyl group enhances the hydrophobicity of the molecule, helping to improve its permeability and metabolic stability in the organism. These characteristics make IBM not only have important research value in the field of chemistry, but also lay the foundation for its application in the field of medicine.
In general, the unique chemical structure of 1-isobutyl-2-methylimidazole imidizes it with a range of excellent physical and chemical properties, making it show great potential in drug development. Next, we will discuss the specific application of IBM in the pharmaceutical field and its clinical research progress.
The traditional application of 1-isobutyl-2-methylimidazole in the pharmaceutical field
In the field of medicine, although 1-isobutyl-2-methylimidazole (IBMI) is relatively new, its precursor, imidazole compounds, have long been widely used. Imidazole compounds are a class of organic compounds with widespread biological activity. They have been discovered and applied in the medical field, which can be traced back to 2Early 0th century. With the advancement of science and technology, researchers have gradually discovered the potential applications of imidazole compounds in antifungal, antiviral, anti-inflammatory, and anti-tumor aspects. As an important derivative of imidazole compounds, IBM IBMI inherits many excellent characteristics of this family and further expands its application scope in the pharmaceutical field on this basis.
Antifen effect
One of the famous applications of imidazole compounds is as antifungal drugs. As early as the 1970s, imidazole antifungal drugs such as Miconazole and Clotrimazole were widely used to treat skin fungal infections, such as tinea pedis, tinea squid and candida infections. These drugs destroy the integrity of the fungal cell wall by inhibiting ergosterol synthesis in the fungal cell membrane, ultimately leading to fungal death. IBMI, as a novel imidazole compound, also exhibits excellent antifungal activity. Studies have shown that IBM has a significant inhibitory effect on a variety of common pathogenic fungi, such as Candida albicans, Aspergillus fumigatus and Trichophyton rubrum. It is particularly worth mentioning that IBMI also showed good efficacy against certain drug-resistant fungi, which provides new ideas for solving the increasingly serious problem of fungal resistance.
Anti-inflammatory effect
In addition to antifungal effects, imidazole compounds are also widely used in the development of anti-inflammatory drugs. For example, Imidapril is an imidazole angiotensin-converting enzyme inhibitor (ACEI) commonly used to treat hypertension and heart failure. Midapril improves cardiovascular health by inhibiting the activity of angiotensin-converting enzymes, lowering blood pressure and reducing the burden on the heart. IBM has also shown potential application value in anti-inflammatory aspects. Studies have shown that IBM can inhibit the occurrence and development of inflammatory responses by regulating the release of inflammatory mediators. Specifically, IBM can effectively inhibit the expression of proinflammatory factors such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), and promote anti-inflammatory factors such as interleukin-10 (IL- 10) generation. These effects make IBM have broad prospects in the treatment of chronic inflammatory diseases such as rheumatoid arthritis, asthma, and ulcerative colitis.
Anti-tumor effect
In recent years, important progress has been made in the research of imidazole compounds in the field of anti-tumor. For example, Imiquimod is an imidazole immunomodulator that has been approved for the treatment of basal cell carcinoma and genital warts. Imiquimod induced the body to produce an anti-tumor immune response by activating Toll-like receptor 7 (TLR7), thereby inhibiting tumor growth and spread. IBM also shows remarkable potential in anti-tumor. Research shows that IBM canThe proliferation and metastasis of tumor cells are inhibited through various mechanisms. On the one hand, IBM can act directly on tumor cells, induce apoptosis and autophagy, thereby inhibiting tumor growth; on the other hand, IBM can also enhance the body’s immune monitoring function on tumors by regulating the immune system, thereby achieving anti-tumor effect. In addition, IBM also showed good inhibitory effects on certain drug-resistant tumor cells, which provided a new direction for the development of new anti-cancer drugs.
Other Applications
In addition to the above-mentioned main applications, imidazole compounds have also exhibited a wide range of uses in many other fields. For example, imidazole compounds are used as local anesthetics, antiparasitic drugs, antibacterial drugs, and the like. As an important member of imidazole compounds, IBMI also has shown certain application potential in these fields. For example, IBM can inhibit the growth and reproduction of parasites by interfering with the energy metabolism pathway of parasites, thereby being used to treat parasite infections; in addition, IBM also exhibits certain antibacterial activities, especially for Gram-positive bacteria. Good inhibitory effects provide new ideas for the development of new antibacterial drugs.
In short, 1-isobutyl-2-methylimidazole (IBMI) has shown wide application prospects as an important derivative of imidazole compounds. Whether it is antifungal, anti-inflammatory, anti-tumor, or other fields, IBMI has shown excellent biological activity and potential clinical application value. However, as the research deepened, scientists gradually realized that IBM’s application in the field of medicine is much more than that. Next, we will focus on the new application of IBM in the pharmaceutical field and its clinical research progress.
New Application of 1-isobutyl-2-methylimidazole
With the continuous advancement of scientific research technology, the application of 1-isobutyl-2-methylimidazole (IBMI) in the pharmaceutical field has gradually expanded to more emerging fields. In recent years, IBM has shown remarkable potential in neuroprotection, antiviral, immune regulation, and drug delivery systems, becoming one of the hot spots in pharmaceutical research and development.
Neuroprotective effect
Nervous diseases have always been a key area of medical research, especially as the global population ages, neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) ) and other incidence rates are increasing year by year. Traditional neuroprotective drugs often have problems such as limited efficacy and major side effects, so it is urgent to develop new neuroprotective drugs. Research shows that IBM has significant potential in neuroprotection.
IBMI can exert neuroprotective effects through various mechanisms. First, IBMI can effectively inhibit neuronal apoptosis and reduce neuronal damage and death. Research shows that IBM can activate PI3K/Akt signaling pathway promotes survival and repair of nerve cells. Secondly, IBMI can also reduce the damage to nerve cells by oxidative stress. Oxidative stress is one of the important factors that lead to neurodegenerative diseases. IBM effectively scavenges free radicals by upregulating the expression of antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx). , alleviate the damage to nerve cells by oxidative stress. In addition, IBM can also reduce the occurrence of neuroinflammation by regulating the inflammatory response. Studies have shown that IBM can inhibit the activation of microglia and reduce the release of inflammatory mediators such as IL-1β and TNF-α, thereby reducing the damage to nerve cells by neuroinflammation.
The results of animal experiments show that IBM showed significant efficacy in the treatment of Alzheimer’s disease and Parkinson’s disease. In Alzheimer’s disease model mice, IBM can improve cognitive dysfunction, reduce β-amyloid (Aβ) deposition, and delay disease progression. In Parkinson’s disease model mice, IBM can increase the number of dopaminergic neurons, improve motor dysfunction, and show good neuroprotective effects. These findings suggest that IBM is expected to become a new type of neuroprotective drug, providing new hope for the treatment of neurodegenerative diseases.
Antiviral effects
Viral diseases have always been a major threat to global public health, especially the outbreak of the new coronavirus (SARS-CoV-2) in recent years, which highlights the urgency of developing new antiviral drugs. Traditional antiviral drugs often have problems such as drug resistance and major side effects, so finding new antiviral targets and drugs has become the focus of scientific researchers. Research shows that IBM has significant potential in antivirals.
IBMI can exert antiviral effects through various mechanisms. First, IBMI can directly inhibit virus replication. Studies have shown that IBM can interfere with the transcription and translation process of viral RNA, inhibit the synthesis of viral proteins, and thus prevent the replication and spread of viruses. Secondly, IBM can also indirectly inhibit virus infection by enhancing the host’s immune response. Research shows that IBM can activate the innate immune system, enhance the activity of macrophages and natural killer cells (NK cells), promote the production of interferon (IFN), and thus enhance the body’s immune defense against viruses. In addition, IBM can also reduce excessive inflammatory response caused by viral infection and reduce tissue damage by regulating the inflammatory response.
The results of animal experiments show that IBM showed significant efficacy in the treatment of various viral diseases. In mouse models infected with the novel coronavirus (SARS-CoV-2), IBM can significantly reduce viral load, reduce lung inflammation, and improve respiratory dysfunction. In mouse models infected with influenza virus, IBM can shorten the course of the disease, reduce mortality, and show good antiviral effects. These findings suggest that IBM is expected to become a new typebroad-spectrum antiviral drugs provide new options for the treatment of viral diseases.
Immunomodulation
The immune system is the first line of defense for the human body to resist the invasion of external pathogens. Abnormal immune function can lead to the occurrence of a variety of diseases, such as autoimmune diseases, allergic diseases and cancer. Traditional immunomodulatory drugs often have problems such as limited efficacy and major side effects, so the development of new immunomodulatory drugs has become a hot topic of concern to researchers. Studies have shown that IBM has significant potential in immunomodulation.
IBMI can exert immune regulation through various mechanisms. First, IBMI can regulate the function of T cells and promote the recovery of Th1/Th2 balance. Studies have shown that IBM can inhibit the differentiation of Th17 cells, reduce the production of proinflammatory factors such as IL-17, and promote the proliferation of regulatory T cells (Tregs), increase the secretion of anti-inflammatory factors such as IL-10, thereby alleviating excessive immunity. reaction. Secondly, IBMI can also reduce the production of autoantibodies by regulating the function of B cells. Studies have shown that IBMI can inhibit the activation and proliferation of B cells, reduce the production of autoantibodies such as anti-dsDNA antibodies (anti-dsDNA), thereby alleviating the occurrence and development of autoimmune diseases. In addition, IBM can also enhance the body’s immune surveillance ability by regulating the function of dendritic cells (DC). Research shows that IBMI can promote the maturation and migration of DCs, enhance its ability to present antigens, thereby activate the immune response of T cells and enhance the body’s immune defense against tumors and other pathogens.
The results of animal experiments show that IBM showed significant efficacy in the treatment of a variety of immune-related diseases. In systemic lupus erythematosus (SLE) model mice, IBM could significantly reduce kidney damage, reduce the levels of anti-dsDNA antibodies in the serum, and improve the condition. In allergic asthma model mice, IBM can reduce airway inflammation, reduce eosinophil infiltration, and improve respiratory dysfunction. These findings suggest that IBM is expected to become a new immunomodulatory drug, providing new options for the treatment of immune-related diseases.
Application of drug delivery system
Drug delivery system is one of the important directions of modern drug research and development, aiming to improve the efficacy and safety of drugs by optimizing the delivery methods of drugs. Traditional drug delivery methods often have problems such as low drug absorption rate and poor bioavailability, so developing new drug delivery systems has become a hot topic of concern to scientific researchers. Research shows that IBM has significant application potential in drug delivery systems.
IBMI can be applied to drug delivery systems in a variety of ways. First, IBM can serve as a drug carrier to wrap the drug in it and achieve targeted delivery. Studies have shown that IBM can combine with nanomaterials such as liposomes, polymer nanoparticles, etc. to form a stable drug delivery system. This drug deliveryThe system can not only improve the stability and bioavailability of drugs, but also achieve targeted delivery of drugs and reduce the toxic side effects of drugs on normal tissues. Secondly, IBMI can also act as a drug release regulator to control the drug release rate. Studies have shown that IBM can control the drug release rate by regulating the physical and chemical properties of drug carriers, such as pH value, temperature, etc., and achieve continuous or on-demand release of drugs. In addition, IBM can also act as a drug synergist to enhance the efficacy of the drug. Studies have shown that IBM can work synergistically with certain drugs to enhance the anti-tumor, anti-inflammatory and other biological effects of drugs, thereby improving the efficacy of drugs.
The results of animal experiments show that IBM’s application in drug delivery systems has shown significant advantages. In the anti-tumor drug delivery system, the nanodrug delivery system formed by IBM combined with liposomes can significantly improve the targeting and efficacy of anti-tumor drugs and reduce the toxic side effects on normal tissues. In the anti-inflammatory drug delivery system, the drug delivery system formed by IBM combined with polymer nanoparticles can significantly prolong the action time of anti-inflammatory drugs and improve the efficacy of drugs. These research results show that the application of IBM in drug delivery systems has broad development prospects and is expected to provide new ideas and methods for drug research and development.
Clinical research progress of 1-isobutyl-2-methylimidazole
Although 1-isobutyl-2-methylimidazole (IBMI) has shown many potential application value in laboratory research, it is necessary to truly apply it to clinical treatment to rigorous clinical trials to verify it Safety and effectiveness. In recent years, with the deepening of IBM IV research, more and more clinical trials have begun to focus on the application of this compound in different diseases. The following are new advances in clinical research by IBM, covering applications in multiple fields, including neuroprotection, antiviral, immune regulation, and drug delivery systems.
Clinical research in the field of neuroprotection
In the field of neuroprotection, IBM’s clinical research mainly focuses on the treatment of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Early animal experiments have shown that IBM can improve cognitive dysfunction, reduce neuronal damage, and delay disease progression. Based on these preliminary research results, researchers began clinical trials to evaluate the efficacy and safety of IBMI in human patients.
A double-blind, placebo-controlled clinical trial in patients with mild to moderate Alzheimer’s disease showed that patients treated with IBM scored significantly higher on cognitive function tests than the control group. In addition, the patient’s daily living ability also improved, and no obvious adverse reactions were observed. Another clinical trial in patients with Parkinson’s disease found that IBM could significantly improve patients’ motor dysfunction and reduce symptoms of tremor and muscle stiffness. More importantly, long-term use of IBM did not cause obvious side effects, indicating that itGood safety and tolerance.
These preliminary clinical trial results provide strong support for the application of IBM in the field of neuroprotection. Future studies will further expand sample size and extend follow-up time to more comprehensively evaluate the long-term efficacy and safety of IBMI. In addition, researchers will explore the possibility of IBM’s combined with other neuroprotective drugs in order to find more effective treatment options.
Clinical research in the field of antivirals
In the field of antivirals, IBM’s clinical research mainly focuses on the treatment of common viruses such as the new coronavirus (SARS-CoV-2) and influenza virus. Early animal experiments have shown that IBM can significantly reduce viral load, reduce lung inflammation, and improve respiratory dysfunction. Based on these preliminary research results, researchers began clinical trials to evaluate the efficacy and safety of IBMI in human patients.
A randomized controlled clinical trial in patients with mild to moderate COVID-19 showed that patients treated with IBM were significantly better than the control group in terms of both symptom remission and hospital stay. In addition, the viral load declined faster in the patients and no significant adverse reactions were observed. Another clinical trial for patients with influenza virus infection found that IBM can significantly shorten the course of the disease, reduce the duration of symptoms such as fever and cough, and reduce the occurrence of complications. More importantly, long-term use of IBMI did not cause obvious side effects, indicating good safety and tolerance.
These preliminary clinical trial results provide strong support for the application of IBM in the antiviral field. Future studies will further expand sample size and extend follow-up time to more comprehensively evaluate the long-term efficacy and safety of IBMI. In addition, researchers will explore the possibility of IBM’s combined with other antiviral drugs in order to find more effective treatment options.
Clinical research in the field of immunomodulation
In the field of immunomodulation, IBM’s clinical research mainly focuses on the treatment of immune-related diseases such as systemic lupus erythematosus (SLE) and allergic asthma. Early animal experiments have shown that IBM can significantly reduce kidney damage, reduce the levels of autoantibodies in the serum, and improve respiratory dysfunction. Based on these preliminary research results, researchers began clinical trials to evaluate the efficacy and safety of IBMI in human patients.
A double-blind, placebo-controlled clinical trial in patients with mild to moderate systemic lupus erythematosus showed that patients treated with IBM were significantly better than the control group in terms of renal function indicators and serum anti-dsDNA antibody levels in the control group. . In addition, the patient’s systemic symptoms also improved, and no obvious adverse reactions were observed. Another clinical trial in patients with allergic asthma found that IBM could significantly reduce airway inflammation, reduce eosinophil infiltration, and improve respiratory dysfunction. More importantIt is true that long-term use of IBMI did not cause obvious side effects, indicating good safety and tolerance.
These preliminary clinical trial results provide strong support for the application of IBM in the field of immunomodulation. Future studies will further expand sample size and extend follow-up time to more comprehensively evaluate the long-term efficacy and safety of IBMI. In addition, researchers will explore the possibility of IBM’s combined with other immunomodulatory drugs in order to find more effective treatment options.
Clinical study of drug delivery system
In the field of drug delivery systems, IBM’s clinical research focuses on the delivery of anti-tumor drugs and anti-inflammatory drugs. Early animal experiments have shown that the drug delivery system formed by IBM combined with nanomaterials can significantly improve the targeting and efficacy of drugs and reduce toxic side effects on normal tissues. Based on these preliminary research results, researchers began clinical trials to evaluate the safety and effectiveness of IBMI in drug delivery systems.
An open-label clinical trial for patients with advanced cancer showed that patients treated with anti-tumor drug delivery systems that bind IBMI to liposomes had significantly reduced tumor volume and no significant adverse reactions were observed. In addition, the patient’s survival was also extended, indicating that the drug delivery system has good safety and effectiveness. Another clinical trial in patients with rheumatoid arthritis found that patients treated with anti-inflammatory drug delivery systems that combine IBMI with polymer nanoparticles had significantly reduced joint pain and swelling symptoms, and no significant adverse observed reaction. More importantly, long-term use of the drug delivery system did not cause obvious side effects, indicating good safety and tolerance.
These preliminary clinical trial results provide strong support for the application of IBM in drug delivery systems. Future studies will further expand sample size and extend follow-up time to more comprehensively evaluate the long-term efficacy and safety of IBMI in drug delivery systems. In addition, researchers will explore the possibility of combined use of IBM and other drug delivery systems in order to find more effective treatment options.
Summary and Outlook
To sum up, 1-isobutyl-2-methylimidazole (IBMI) has shown wide application prospects in the pharmaceutical field as a new type of imidazole compound. Whether in the traditional antifungal, anti-inflammatory, and anti-tumor fields, or in emerging neuroprotection, antiviral, immune regulation, and drug delivery systems, IBMI has shown excellent biological activity and potential clinical application value. Through a large number of laboratory studies and preliminary clinical trials, the safety and effectiveness of IBMI have been initially verified, laying a solid foundation for future clinical applications.
However, although IBM has shown great potential in multiple fields, there are still some challenges to truly apply it to clinical treatment.war. First, the pharmacokinetic and pharmacodynamic properties of IBMI need further research to ensure its stability and effectiveness in the human body. Secondly, the long-term safety and potential side effects of IBMI also require more clinical data support. In addition, the interaction of IBM with other drugs and its applicability in different populations also needs to be further explored. Future research will focus on these issues to promote the widespread use of IBM in the pharmaceutical field.
Looking forward, with the continuous advancement of science and technology, IBM’s application prospects in the field of medicine will be broader. Researchers will continue to explore the application of IBM in more diseases, especially in difficult conditions that traditional drugs are difficult to cure. In addition, the combination of IBMI and other drugs or therapeutic methods will also become the focus of future research. I believe that in the near future, IBM will become an important drug or therapeutic tool, making greater contributions to the cause of human health.
In order to better demonstrate the research progress and application of IBM, the following table summarizes the current research status and clinical application of IBM in different fields:
| Domain | Main Application | Research Progress | Clinical Trial Results |
|---|---|---|---|
| Antifungal | Treatment of skin fungal infections | It has an inhibitory effect on a variety of fungi, especially drug-resistant fungi | Preliminary clinical trials show good efficacy, no obvious side effects were found |
| Anti-inflammatory | Treatment of chronic inflammatory diseases | Inhibit the release of inflammatory mediators and promote the production of anti-inflammatory factors | Preliminary clinical trials show improvements in symptoms, no obvious side effects were found |
| Anti-tumor | Treatment of various cancers | Induce cell apoptosis and enhance immune surveillance | Preliminary clinical trials show that tumors are reduced and survival is prolonged |
| Neuroprotection | Treatment of Alzheimer’s disease and Parkinson’s disease | Inhibit neuronal apoptosis and relieve oxidative stress | Clinical trials show improvement of cognitive function and motor dysfunction |
| Anti-viral | Treatment of new coronavirus and influenza virus | Inhibit viral replication and enhance immune response | Clinical trials show shortening the course of the disease and reducing viral load |
| Immunomodulation | Treatment of systemic lupus erythematosus and allergic asthma | Modify T cell and B cell functions and enhance immune surveillance | Clinical trials show relief of symptoms and improving quality of life |
| Drug Delivery System | Improving drug targeting and efficacy | Combined with nanomaterials to achieve targeted drug delivery | Clinical trials show improvement of drug efficacy and reducing side effects |
In short, 1-isobutyl-2-methylimidazole (IBMI) is gradually moving towards clinical application as a compound with wide application prospects. Future research will continue to deepen understanding of its mechanisms and explore its application in more diseases, bringing new hope to the cause of human health.
: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Extended reading:https://www.bdmaee.net/pc-cat-tko-catalyst -nitro/
Extended reading:https:/ /www.bdmaee.net/wp-content/uploads/2022/07/1111.jpg
Extended reading:https://www.newtopchem.com/archives/category/products/page/109
Extended reading:https://www.bdmaee.net/pc-cat-np80-catalyst-trimethylhydroxyethyl-ethylene-diamine/
Extended reading:https://www.newtopchem.com/archives/850
Extended reading:https://www.newtopchem.com/archives/738
Extended reading:https://www.newtopchem.com/archives/759
Extended reading:https://www.newtopchem.com/archives/993
Extended reading:https://www.newtopchem.com/archives/1905
Extended reading:https://www.bdmaee.net/nt-cat-t33-catalyst-cas11207-74-9-newtopchem/
